<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862221</url>
  </required_header>
  <id_info>
    <org_study_id>PALF IRN/TRIUMPH</org_study_id>
    <secondary_id>U01DK062436</secondary_id>
    <nct_id>NCT04862221</nct_id>
  </id_info>
  <brief_title>TReatment for ImmUne Mediated PathopHysiology</brief_title>
  <acronym>TRIUMPH</acronym>
  <official_title>A Phase 2b, Double-Blind, Three Arm, Randomized, Placebo Controlled Trial With Restricted Response Adaptive Randomization Testing the Efficacy and Safety of High Dose Methylprednisolone or Equine Anti-Thymocyte Globulin as Treatment for Acute Liver Failure in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm,&#xD;
      randomized, controlled trial of immunosuppressive therapy for children with acute liver&#xD;
      failure. The study will determine if suppressing inflammatory responses with either&#xD;
      corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with&#xD;
      this rare, life-threatening condition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric Acute Liver Failure (PALF) is a rare, devastating condition that affects an&#xD;
      estimated 250 children per year in North America, causing death in approximately 15% and the&#xD;
      need for liver transplantation in an additional 20-30%. In the majority of cases, a specific&#xD;
      cause of the liver injury is never determined. Recent research supports the theory that many&#xD;
      of these patients have liver injury related to a hyperinflammatory immune response to&#xD;
      everyday infections or environmental exposures. There is strong evidence to show that equine&#xD;
      anti-thymocyte globulin and methylprednisolone slow the body's response to inflammation and&#xD;
      improve the recovery of patients with other immune disorders and thus, may help patients with&#xD;
      acute liver failure.&#xD;
&#xD;
      This is a phase 2b, double-blind, three arm, randomized, placebo controlled trial with&#xD;
      restricted response adaptive randomization. The primary objective is to determine the&#xD;
      efficacy and safety of high-dose methylprednisolone or equine anti-thymocyte globulin (eATG&#xD;
      or ATGAM®) as compared to supportive care alone (placebo) for the treatment of acute liver&#xD;
      failure in pediatric patients.&#xD;
&#xD;
      Approximately 160 patients who are equal to or greater than ≥ 1 and less than ≤ 18 years of&#xD;
      age with pediatric acute liver failure (PALF) of undetermined etiology will be randomized to&#xD;
      receive either high-dose methylprednisolone (Treatment 1) or eATG (ATGAM®) (Treatment 2) or&#xD;
      supportive care alone (Treatment 3) on days 1 to 4 after study enrollment, followed by a&#xD;
      gradual prednisolone taper (for the two active treatment arms 1 and 2) or a placebo taper&#xD;
      (for treatment arm 3) on days 5 to 42.&#xD;
&#xD;
      The follow-up period includes visits at 1 week (Day 7), 2 weeks (Day 14), and 3 weeks (Day&#xD;
      21) after the day the participant started in the study. Early follow-up assessments will be&#xD;
      performed either in the inpatient or ambulatory setting since some participants may be&#xD;
      discharged before Day 7. In addition, families will be contacted by phone or email to&#xD;
      schedule each follow-up at the study site for the 6 week, 3 month, 6 month and 12 month study&#xD;
      visits.&#xD;
&#xD;
      The findings of this trial have the potential to shift the treatment paradigm in PALF and&#xD;
      advance the basic understanding of immune dysregulation disorders in childhood. The network&#xD;
      includes 20 of the largest and most active pediatric liver centers in the US who have&#xD;
      organized to support rigorous testing of the efficacy and safety of immunosuppressive therapy&#xD;
      for these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival with native liver (SNL)</measure>
    <time_frame>21 days</time_frame>
    <description>Alive and without a liver transplant 21 days following randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival with native liver (SNL)</measure>
    <time_frame>180 days</time_frame>
    <description>Alive and without a liver transplant 6 months (180 days) following randomization</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Acute Liver Failure</condition>
  <condition>Fulminant Hepatic Failure</condition>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Acute Liver Injury</condition>
  <condition>Immune Dysregulation</condition>
  <arm_group>
    <arm_group_label>High-dose methylprednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous methylprednisolone at an initial dose of 10 mg/kg/day for 3 days, 5 mg/kg/day on day 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Equine anti-thymocyte globulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous equine anti-thymocyte globulin at a dose of 40 mg/kg/day for 4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supportive care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Supportive care will be administered as determined by the clinical team at participating clinical sites in accordance with their local practices and standards.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose methylprednisolone</intervention_name>
    <description>Subjects in the high-dose methylprednisolone arm will receive an initial dose of methylprednisolone IV 10 mg/kg/day for 3 days and 5 mg/kg/day on Day 4. Normal saline will be used as placebo pre-medications and infusions given at the same volume and duration as the eATG infusions.</description>
    <arm_group_label>High-dose methylprednisolone</arm_group_label>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Equine anti-thymocyte globulin</intervention_name>
    <description>Subjects will receive eATG IV 40 mg/kg/day on Days 1- 4. Day 1 eATG infusion is run over 8 hours and Day 2-4 infusions are run over 4 hours.</description>
    <arm_group_label>Equine anti-thymocyte globulin</arm_group_label>
    <other_name>ATGAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Subjects will receive prednisolone 1 mg/kg on Days 5-13 followed by a gradual taper with discontinuation at 42 Days as indicated below.&#xD;
Days 5 - 13 Prednisolone PO 1 mg/kg/day (max 50 mg/day)&#xD;
Days 14- 20 Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)&#xD;
Days 21 - 27 Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)&#xD;
Days 28 - 34 Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)&#xD;
Days 35 - 41 Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)&#xD;
Day 42 Discontinue</description>
    <arm_group_label>Equine anti-thymocyte globulin</arm_group_label>
    <arm_group_label>High-dose methylprednisolone</arm_group_label>
    <other_name>15 mg/mL oral solution National Drug Code: 50383-0042-24</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for prednisolone</intervention_name>
    <description>Subjects will receive 1 mg/kg/day of oral placebo for prednisolone on days 5-13 followed by a gradual taper to discontinuation at 42 days as indicated below. Subjects receiving oral placebo will be given a solution that closely resembles the treatment drug.&#xD;
Days 5 - 13 Placebo for Prednisolone PO 1 mg/kg/day (max 50 mg/day)&#xD;
Days 14- 20 Placebo for Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)&#xD;
Days 21 - 27 Placebo for Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)&#xD;
Days 28 - 34 Placebo for Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)&#xD;
Days 35 - 41 Placebo for Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)&#xD;
Day 42 Discontinue</description>
    <arm_group_label>Supportive care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for infusions</intervention_name>
    <description>Subjects randomized to the supportive care alone arm will receive normal saline in place of all study treatments (skin test, premedication and IV infusions) on Days 1-4 given at the same volume and duration as the eATG infusions.</description>
    <arm_group_label>Supportive care</arm_group_label>
    <other_name>0.9% Sodium chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Subjects in the eATG arm will receive pre-treatment medication diphenhydramine IV 1 mg/kg prior to start of eATG infusion.</description>
    <arm_group_label>Equine anti-thymocyte globulin</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Subjects in the eATG arm will receive pre-treatment medication methylprednisolone IV 1 mg/kg prior to start of eATG infusion.</description>
    <arm_group_label>Equine anti-thymocyte globulin</arm_group_label>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with liver injury of ≤ 6 weeks duration resulting in an international&#xD;
             normalized ratio (INR) of ≥ 1.5 and &lt; 2.0 (not corrected by vitamin K) with evidence&#xD;
             of hepatic encephalopathy (HE) or INR ≥ 2.0 without evidence of HE.&#xD;
&#xD;
          2. Age is greater than or equal to 1 year and less than 18 years of age.&#xD;
&#xD;
          3. Patient or their legally authorized representative(s) (LAR) must consent (and assent,&#xD;
             if applicable) to be in the study and must have signed and dated an approved informed&#xD;
             consent form which conforms to federal and institutional guidelines.&#xD;
&#xD;
          4. Females of reproductive potential should not plan on conceiving children during the&#xD;
             study and must agree to use a medically accepted form of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of active infection with Hepatitis A, B, C, E or evidence of acute herpes&#xD;
             simplex virus (HSV) or adenovirus infection&#xD;
&#xD;
          2. Travel within the past 3 months to an area highly endemic for Hepatitis E&#xD;
&#xD;
          3. Diagnosis of hemophagocytic lymphohistiocytosis (HLH) Note: Patients with a history of&#xD;
             consanguinity and/or central nervous system (CNS) dysfunction that is exaggerated&#xD;
             compared to the degree of liver dysfunction (as judged by the site investigator) will&#xD;
             not be enrolled until results of rapid genetic testing are available. Turn-around time&#xD;
             for genetic testing results is estimated to be 72-96 hours.&#xD;
&#xD;
          4. Aplastic anemia as defined by standardized criteria [1] diagnosed prior to enrollment&#xD;
&#xD;
          5. Diagnosis of autoimmune Hepatitis (AIH)&#xD;
&#xD;
          6. Diagnosis of acute Wilson disease&#xD;
&#xD;
          7. Diagnosis of inborn error of metabolism Note: Suspicion of metabolic disease is not an&#xD;
             exclusion for entry into the Trial.&#xD;
&#xD;
          8. Diagnosis of acute drug or toxin-induced liver injury&#xD;
&#xD;
          9. History of recreational drug use within the past 4 weeks&#xD;
&#xD;
         10. Therapy with an immunosuppressive agent, including chemotherapy, biological therapies&#xD;
             or an experimental drug or device within the past 6 weeks&#xD;
&#xD;
         11. Liver injury due to ischemia&#xD;
&#xD;
         12. Liver dysfunction diagnosed more than 6 weeks prior to screening&#xD;
&#xD;
         13. History of allergy to horse dander&#xD;
&#xD;
         14. Sepsis&#xD;
&#xD;
         15. Imminent risk of death as judged by the clinical site investigator, including but not&#xD;
             limited to; signs of cerebral herniation at the time of enrollment and presence of&#xD;
             intractable arterial hypotension&#xD;
&#xD;
         16. Solid organ or stem cell transplant recipient&#xD;
&#xD;
         17. Pregnant or breast-feeding at the time of proposed study entry&#xD;
&#xD;
         18. Clinical AIDS or HIV positive&#xD;
&#xD;
         19. History of any form of malignant neoplasm and/or tumors treated within five years&#xD;
             prior to study entry (other than non-melanoma skin cancer or in situ cervical cancer)&#xD;
             or where there is current evidence of recurrent or metastatic disease&#xD;
&#xD;
         20. Received a live-virus vaccine within 4 weeks of study entry&#xD;
&#xD;
         21. Positive test result for the severe acute respiratory syndrome coronavirus 2&#xD;
             (SARS-CoV-2) infection&#xD;
&#xD;
         22. Psychiatric or addictive disorders that would preclude obtaining informed&#xD;
             consent/assent&#xD;
&#xD;
         23. Patient is unwilling or unable to adhere with study requirements and procedures&#xD;
&#xD;
         24. Currently receiving other experimental therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Estella M Alonso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valerie L Durkalski-Mauldin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ed Doo, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Averell Sherker, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katie Neighbors, MPH</last_name>
    <phone>312-227-4557</phone>
    <email>kneighbors@luriechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristen M Clasen</last_name>
    <phone>843-792-7243</phone>
    <email>clasen@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Beth Carter, MD</last_name>
      <phone>323-361-5454</phone>
      <email>becarter@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Beth Carter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>William Berquist, MD</last_name>
      <phone>650-723-5070</phone>
      <email>berquist@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>William Berquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Philip Rosenthal, MD</last_name>
      <phone>415-476-5892</phone>
      <email>prosenth@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Philip Rosenthal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shikha Sundaram, MD</last_name>
      <phone>720-777-6669</phone>
      <email>shikha.sundaram@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Shikha Sundaram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Children's Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Pamela Valentino, MD MSc</last_name>
      <phone>203-785-4649</phone>
      <email>pamela.valentino@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela Valentino, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rene Romero, MD</last_name>
      <phone>404-785-1832</phone>
      <email>Rene.Romero@choa.org</email>
    </contact>
    <investigator>
      <last_name>Rene Romero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine Chapin, MD</last_name>
      <phone>312-227-5511</phone>
      <email>cchapin@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Catherine Chapin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Girish Rao, MD</last_name>
      <phone>317-944-3774</phone>
      <email>gsrao@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Girish Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Scott Elisofon</last_name>
      <phone>617-355-5837</phone>
      <email>Scott.Elisosfon@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Elisofon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ryan Fischer, MD</last_name>
      <phone>816-302-3410</phone>
      <email>rtfischer@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Rudnick, MD PhD</last_name>
      <phone>314-286-2832</phone>
      <email>rudnick_d@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>David Rudnick, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jaime Chu, MD</last_name>
      <phone>212-659-8060</phone>
      <email>Jaime.Chu@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Jaime Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center - Duke Children's</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alisha Mavis</last_name>
      <phone>919-684-5068</phone>
      <email>alisha.mavis@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Alisha Mavis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kathleen Loomes, MD</last_name>
      <phone>267-426-7223</phone>
      <email>LOOMES@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Loomes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>James Squires, MD</last_name>
      <phone>412-692-5180</phone>
      <email>james.squires2@chp.edu</email>
    </contact>
    <investigator>
      <last_name>James Squires, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center Children's Health</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Norberto Rodriguez-Baez, MD</last_name>
      <phone>214-456-7436</phone>
      <email>Norberto.Rodriguez-Baez@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Norberto Rodriguez-Baez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna Banc-Husu, MD MSCI</last_name>
      <phone>832-822-3624</phone>
      <email>anna.banc-husu@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Anna Banc-Husu, MD MSCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kyle Jensen, MD</last_name>
      <phone>801-213-3599</phone>
      <email>kyle.jensen@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Kyle Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Evelyn Hsu, MD</last_name>
      <phone>206-987-2521</phone>
      <email>evelyn.hsu@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Evelyn Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatic insufficiency</keyword>
  <keyword>liver diseases</keyword>
  <keyword>liver failure</keyword>
  <keyword>anti-thymocyte agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be available at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository. The public use dataset, along with the study protocol, the data dictionary, annotated case report forms and a brief set of instructions (&quot;Readme&quot; file) will be provided.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Release of the public use dataset will follow the NIDDK guidelines of within six months of the publication date for the primary outcome publication or within two years of the date that the database is locked for analysis, whichever occurs first.</ipd_time_frame>
    <ipd_url>https://repository.niddk.nih.gov/home/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

